Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2016

View Archived Issues

Adjuvanted rabies vaccine from Yisheng Biopharma given U.S. orphan drug status for HCC

Advaxis initiates phase III trial of ADXS-11-001 in high-risk locally advanced cervical cancer

Celgene initiates first-in-human study of CC-90009 in relapsed or refractory AML

Imago initiates phase I trial of IMG-7289 in patients with advanced myeloid malignancies

Apitope regains global rights to ATX-MS-1467 from Merck KGaA

Omeros reports phase II data for OMS-721, pursuing FDA breakthrough therapy designation

Pfizer to begin shipping Inflectra next month

89Zr-Girentuximab imaging evaluated in first-in-human renal cell carcinoma study

Addex Therapeutics to initiate phase IIa trial of dipraglurant in focal cervical dystonia

European Commission approves Onivyde

Envisia Therapeutics releases interim data from ENV-515 phase II trial

EMA gives orphan drug designation to Eiger's exendin 9-39

FDA accepts NDA resubmission for sodium zirconium cyclosilicate

Positive opinion handed down in E.U. for SomaKit TOC

Responses seen with cabozantinib plus nivolumab in patients with genitourinary tumors

Sichuan Haisco Pharmaceutical patents M3 receptor antagonists and/or beta2-adrenoceptor agonists

Mutabilis discloses beta-lactamase inhibitors

Takeda Pharmaceutical describes MGL inhibitors

Jubilant Biosys develops HUNK1 inhibitors

Toray Industries presents kappa-opioid agonists

Regeneron and Teva update status of fasinumab programs

MYH7 mutations may be involved in nemaline myopathies with cardiomyopathy

PTC Therapeutics offers U.S. and E.U. regulatory update on Translarna

RYR3 variants may cause nemaline myopathy and fiber type disproportion

Zynerba offers updates on lead programs ZYN-001 and ZYN-002

Brain imaging successful with [11C]CB-184 in healthy human subjects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...